1. ALLA AKTIER
  2. NYHETER
  3. ABLIVA

Abliva

Nyheter Abliva Nyheter alla bolag

Abliva AB Interim Report January – June 2022

REG

SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies

Second quarter summary

Important events second quarter (Apr - Jun 2022)

  • On June 1, Abliva’s Board of Directors announced funding of approximately SEK 200 million that is expected to provide the company with the capital required to pursue the Phase 2/3 study with KL1333 to a key interim analysis, as well as prepare NV354 for clinical phase.
  • Annual General Meeting was held on May 20, 2022. All proposals were approved, including the re-election of the Board of Directors.

Financial information
April-June 2022*

  • Net revenues: SEK 0,000 (18,000)
  • Other operating income: SEK 0,000 (0,000)
  • Loss before tax: SEK 20,535,000 (30,314,000)
  • Loss per share before dilution: SEK 0.04 (0.08)
  • Diluted loss per share: SEK 0.04 (0.08)

January-June 2022*

  • Net revenues: SEK 0,000 (18,000)
  • Other operating income: SEK 0,000 (0,000)
  • Loss before tax: SEK 42,564,000 (51,770,000)
  • Loss per share before dilution: SEK 0.09 (0.13)
  • Diluted loss per share: SEK 0.09 (0.13)

* APM Alternative performance measures, see definition on page 20.

The complete Interim report is available for download below and through Abliva's website www.abliva.com.

This information is information that Abliva AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 2022-08-19 08:30 CEST.

For more information, please contact:

Catharina Johansson, Deputy CEO, CFO & VP Investor Relations
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

Subscribe to our news: https://abliva.com/posts/news-subscription/
Follow us on LinkedIn: https://www.linkedin.com/company/abliva
Subscribe to our YouTube channel: https://www.youtube.com/channel/UChqP7Ky5caXtp72CELhD6Mg

Abliva – Delivering mitochondrial health

Abliva discovers and develops medicines for the treatment of primary mitochondrial diseases. These rare and often very severe diseases occur when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, is entering late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

Abliva Q2 2022 EN

Datum 2022-08-19, kl 08:30
Källa MFN
Bifogade filer
Abliva Q2 2022 EN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!